Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL2-BIO: Sequential Bendamustine, Ofatumumab, and Ibrutinib in CLL
NCT02689141Phase 2Completed
- Sponsor
- German CLL Study Group
- Start
- Feb 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, ofatumumab in chronic lymphocytic leukemia (CLL), sponsored by German CLL Study Group. Started Feb 2016; status: completed.
02
Drugs
ibrutinibofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02689141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689141.